非经营性资金占用及其他关联资金往来情况汇总表 单位：万元 江苏澳洋健康产业股份有限公司 2023 年半年度 | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公司的 | 上市公司核算的 | 2023 年期初占 | 2023 年半年度 占用累计发生金 | 2023 年半年 度占用资金的 | 2023 年半年度 2023 偿还累计发生金 | 年 6 月占用 | 占用形成原因 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 关联关系 | 会计科目 | 用资金余额 | 额（不含利息） | 利息(如有) | 额 | 资金余额 | | | | | | | | | | | | | | 非经营性占用 | | 控股股东、实际控 制人及其附属企业 | | | | | | | | | | | | | | | | | | | | | | 非经营性占用 | | 小计 | - | - | - | | | | | | - | - | | 前控股股东、实际 | | | | | | | | | | 非经营性占用 | | ...

江苏澳洋健康产业股份有限公司独立董事 关于控股股东及其他关联方占用公司资金、公司对外担保情况 的专项说明和独立意见 根据《上市公司独立董事规则》、《深圳证券交易所上市公司自律监管指引第 1号——主板上市公司规范运作》及《公司章程》等有关规定，作为公司的独立董 事，我们本着实事求是的态度，依据客观公正的原则，对公司截至2023年6月30日的 控股股东及其他关联方占用公司资金情况、公司对外担保情况、募集资金使用情况 等进行了核查，核查情况如下： 根据中国证监会《上市公司监管指引第8 号——上市公司资金往来、对外担保 的监管要求》及《深圳证券交易所股票上市规则》《公司章程》的有关规定，作为 公司独立董事，我们本着对公司、全体股东负责的态度，我们对控股股东及其他关 联方占用公司资金、公司对外担保情况进行了认真的核查，认为公司严格执行国家 的有关法律法规，加强资金管理、对外担保管理，严格控制资金往来及对外担保风 险。公司与控股股东及关联方的资金往来属于正常的经营性资金往来，控股股东及 关联方不存在非经营性占用公司资金的情形。现发表独立意见如下： 1、截至2023年6月30日，公司与控股股东及其子公司、其他关联方不存在关 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥543,869,982.70, a decrease of 15.49% compared to ¥643,577,490.50 in the same period last year[3] - Net profit attributable to shareholders was ¥36,326,684.73, representing an increase of 11.78% from ¥32,498,869.97 year-on-year[3] - The net profit after deducting non-recurring gains and losses was ¥11,677,474.17, down 70.62% from ¥39,746,660.40 in the previous year[3] - Basic and diluted earnings per share increased by 25.00% to ¥0.05 from ¥0.04 year-on-year[3] - Total operating revenue for Q1 2023 was CNY 543.87 million, a decrease of 15.5% compared to CNY 643.58 million in Q1 2022[15] - Net profit for Q1 2023 reached CNY 36.66 million, an increase of 11.4% from CNY 32.79 million in Q1 2022[16] - The company's total assets decreased to CNY 2.55 billion in Q1 2023 from CNY 2.71 billion in Q1 2022, a decline of 5.8%[12] - The company's equity attributable to shareholders increased to CNY 80.59 million in Q1 2023 from CNY 44.26 million in Q1 2022, a growth of 82%[13] Cash Flow and Liquidity - The net cash flow from operating activities improved by 62.46%, reaching -¥121,279,156.93 compared to -¥323,103,011.47 in the same period last year[3] - The net cash flow from financing activities decreased by 95.20% compared to the previous year, attributed to no inter-company borrowing repayments during the period[8] - The net increase in cash and cash equivalents decreased by 227.27% year-on-year, primarily due to a significant increase in cash from the disposal of long-term assets in the previous period[8] - The cash and cash equivalents at the end of the reporting period were 722,967,577.03 yuan, down from 984,155,292.34 yuan at the beginning of the year[11] - The company’s cash and cash equivalents decreased to CNY 744.11 million in Q1 2023 from CNY 755.60 million in Q1 2022[12] - Total cash inflow from financing activities was 551,934,820.35 CNY, while cash outflow was 567,103,261.31 CNY, resulting in a net cash flow of -15,168,440.96 CNY[19] - Cash received from sales of goods and services was 496,348,199.74 CNY, a decrease from 533,277,746.93 CNY year-over-year[18] Investment and Assets - Investment income for the period was ¥25,827,820.99, a significant increase from a loss of ¥142,691.76 in the same period last year[6] - The company recognized a non-recurring gain of 25,827,820.99 yuan from the sale of its wholly-owned subsidiary, Jiangsu Aoyang New Materials Technology Co., Ltd.[9] - The total current assets at the end of the reporting period amounted to 1,651,777,974.50 yuan, down from 1,808,681,669.58 yuan at the beginning of the year[11] - The balance of accounts receivable increased to 394,589,122.04 yuan from 314,453,133.56 yuan at the beginning of the year[11] - The company reported a total cash inflow from operating activities of 680,114,077.87 CNY, down from 750,511,190.57 CNY in the previous period[18] - The company’s cash flow from investment activities showed a net outflow of -19,806,545.73 CNY, contrasting with a net inflow of 761,728,828.43 CNY in the previous period[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 63,763[8] - The largest shareholder, Aoyang Group Co., Ltd., holds 30.74% of shares, amounting to 235,349,599 shares, with 116,686,547 shares pledged[8] Costs and Expenses - Total operating costs for Q1 2023 were CNY 524.02 million, down 19.6% from CNY 651.94 million in the same period last year[15] - The company experienced a 71.62% reduction in financial expenses due to a decrease in total borrowings and corresponding interest expenses[6] - Cash used for debt repayment decreased by 60.12% compared to the same period last year, primarily due to a reduction in loan repayment amounts[8] - Cash paid for dividends and interest increased by 67.88% year-on-year, mainly due to an increase in dividends paid to minority shareholders[8] - The company paid 551,296,828.73 CNY for purchasing goods and services, down from 845,188,472.01 CNY in the previous period[18] - The cash outflow for other investment activities was 25,987,067.34 CNY, compared to 189,074,637.19 CNY in the previous period[19]

Business Transformation - The company reported a significant shift in focus towards the healthcare sector after divesting its non-core business, with full commitment to medical health operations as of May 7, 2022[18]. - The company has undergone a transformation from primarily producing viscose staple fiber to establishing a dual business model in chemical fibers and health industries since 2015[17]. - The company completed the asset transfer and announced the completion of the transaction on May 7, 2022, marking a full transition to the health industry[93]. - The company divested from its chemical fiber business to focus entirely on the healthcare sector, aligning with its strategic transformation[88]. Financial Performance - The company's operating revenue for 2022 was ¥2,021,311,317.17, a decrease of 33.27% compared to ¥3,028,918,811.03 in 2021[20]. - The net profit attributable to shareholders was -¥15,389,790.15 in 2022, showing an improvement of 98.52% from -¥1,038,913,881.13 in 2021[20]. - The total assets at the end of 2022 were ¥2,708,031,538.51, down 29.17% from ¥3,823,219,194.07 at the end of 2021[20]. - The company reported a basic and diluted earnings per share of -¥0.02 in 2022, an improvement of 98.51% from -¥1.34 in 2021[20]. - The company reported a loss of ¥22,202,585.29 from investment income, representing 2,302.57% of total profit[65]. Revenue Breakdown - Revenue from medical services increased by 6.18% to CNY 1,006,694,205.21, accounting for 49.80% of total revenue[51]. - Revenue from pharmaceutical logistics decreased by 2.88% to CNY 997,697,746.78, representing 49.36% of total revenue[51]. - The total revenue for Jiangsu Aoyang Health Industry Co., Ltd. in 2022 was 613.84 million RMB, showing a significant increase compared to the previous year[105]. - The company reported a total revenue of 688.6 million with a growth rate of 64.88% compared to the previous year[152]. Strategic Initiatives - The company aims to enhance its brand and expand specialty services, focusing on building a high-level research institute in oncology[47]. - The company is actively pursuing investment opportunities in the medical service industry to strengthen its competitive position in East China[47]. - The company aims to optimize assets and upgrade the health industry and brand, focusing on the integration of medical, health, and elderly care services[94]. - The company is focusing on expanding its market presence in the health industry through strategic procurement[152]. Market Trends - The healthcare industry in China has shown a compound annual growth rate (CAGR) of 10.58% in total health expenditure from 2012 to 2021, reaching ¥76,844.99 billion[32]. - The number of private hospitals in China increased from 9,786 in 2012 to 24,766 in 2021, representing a compound annual growth rate of 9.73%[38]. - The total number of hospitals in China grew from 23,170 in 2012 to 36,570 in 2021, with the proportion of private hospitals rising from 42.24% to 67.72%[38]. Governance and Compliance - The company’s financial report is guaranteed to be true, accurate, and complete by its board of directors and management, ensuring accountability[3]. - The company has engaged Lixin Certified Public Accountants for auditing, ensuring compliance and transparency in financial reporting[19]. - The company has maintained a stable governance structure, complying with relevant laws and regulations without any major issues[135]. Employee and Management Information - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 3.64 million[116]. - The total number of employees at the end of the reporting period was 2,274, with 1,499 being technical personnel, representing approximately 66% of the workforce[124]. - The company conducted various training programs throughout the year, covering management, chemical fiber professional skills, and medical professional skills[127]. Future Outlook - The company plans to expand its market presence by entering three new provinces in 2023, aiming for a 25% increase in market share[108]. - The company has set a performance guidance for 2023, targeting a revenue growth of 30% compared to 2022[108]. - Future guidance includes an expected EBITDA margin improvement of 3% as a result of strategic investments and operational efficiencies[154]. Legal Matters - The company is involved in a lawsuit with a claim amount of ¥4,011.05 million, which has been recognized as a liability[147]. - Another lawsuit involves a claim amount of ¥2,616.29 million, with the court proceedings already initiated[147]. - The company has settled a dispute involving a claim of ¥1,682.42 million, with the execution of the settlement completed[148]. Risk Management - The company has acknowledged potential risks related to national policies affecting the healthcare industry, urging investors to remain aware of investment risks[3]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[138]. - The company has not encountered any bankruptcy reorganization matters during the reporting period[146].

江苏澳洋健康产业股份有限公司 关于举行 2022 年年度报告业绩说明会的通知 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚 假记载、误导性陈述或者重大遗漏负连带责任。 江苏澳洋健康产业股份有限公司《2022 年年度报告》全文及摘要已于 2023 年 3 月 23 日经公司第八届董事会第十次会议审议通过。《2022 年年度报告》全 文及摘要已于 2023 年 3 月 24 日刊登于巨潮资讯网站（http://www.cninfo.com.cn） 上，《2022 年年度报告摘要》同时刊登在《证券时报》上，供全体股东和投资者 查询。 为使广大投资者进一步详细了解公司年报信息，公司定于 2023 年 4 月 7 日 （星期五）15:00-17:00 在深圳证券信息有限公司提供的网上平台举行年度报告 说明会，本次年度报告说明会将采用网络远程的方式举行，投资者可登录"全景 •路演天下"（http://rs.p5w.net）参与公司年度报告说明会。 关于举行 2022 年年度报告业绩说明会的通知 证券代码：002172 证券简称：澳洋健康 公告编号：2023-18 届时公司董事长兼总经理沈学如先生，董事 ...

证券代码：002172 证券简称：澳洋科技 江苏澳洋科技股份有限公司投资者关系活动记录表 编号：2015-02 | --- | --- | --- | |-----------------------|-------------------------|----------------------------------------------------------| | | | | | | | 特定对象调研 □分析师会议 | | 投资者关系活动 | □ | 媒体采访 □业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 富国基金 宋哲建；国泰君安 胡昂；华宝兴业基金 徐程惠； | | 人员姓名 | | 海富通基金 张坤；交银施罗德 牛明俊；信邦投资 姚炳峰； | | | 钟玮玮 蔡宜韬 金伟彪 | | | 时间 | 2015 年 7 月 20 | 日 | | 地点 | | 江苏澳洋科技股份有限公司会议室 | | 上市公司接待人 员姓名 | 宋满元、季超 | | | 投资者关系活动 | ...

证券代码：002172 证券简称：澳洋科技 江苏澳洋科技股份有限公司投资者关系活动记录表 编号：2015-03 | --- | --- | --- | |-----------------------|-------------------------|--------------------------------------------------------| | | | | | | | 特定对象调研 □分析师会议 | | 投资者关系活动 | □ | 媒体采访 □业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 长城证券 陈宏亮；平安证券 郭哲 | | 人员姓名 | | | | 时间 | 2015 年 7 月 28 | 日 | | 地点 | | 江苏澳洋科技股份有限公司会议室 | | 上市公司接待人 员姓名 | 宋满元、季超 | | | 投资者关系活动 | 一、粘胶短纤业务情况 | | | 主要内容介绍 | | 答：近期市场各方对粘胶市场价格上涨趋势较为认同，公司 | | | | ...

证券代码：002172 证券简称：澳洋科技 江苏澳洋科技股份有限公司投资者关系活动记录表 编号：2015-01 | --- | --- | --- | |----------------|--------------------------------|------------------------------------------------------------| | | | | | | | 特定对象调研 □分析师会议 | | 投资者关系活动 | □ | 媒体采访 □业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 通金投资 陈坤、国信证券 苏淼、华安基金 袁银泉、中国人寿资 | | 人员姓名 | | 管 赵文龙、国海富兰克林基金 张琼钢、兴业证券 郑方镳 李鸣 | | | | 孙佳丽、细水投资 刘伟、鸿道投资 应振洲、农银汇理基金 徐治 | | | | 彪 陈继业、华安基金 周阳、中银基金 王帅、东吴人寿 张亚辉、 | | | | 汇添富基金 李华伟、东方资管 周云 蔡志鹏 ...

证券代码：002172 证券简称：澳洋科技 江苏澳洋科技股份有限公司投资者关系活动记录表 编号：2016-02 | --- | --- | --- | |-----------------------|-------------------------|---------------------------------------------------------| | | | | | | | 特定对象调研 □分析师会议 | | 投资者关系活动 | □ | 媒体采访 □业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 中金公司 高峥、唐卓菁；申万宏源 何婧雯、张颢译；国海证 | | | | 券 梁欢；华创证券 蔡春根；大成基金 李博、韩创；银华基金 | | 人员姓名 | 王丽敏。 | | | 时间 | 2016 年 2 月 18 | 日 | | 地点 | | 江苏澳洋科技股份有限公司会议室 | | 上市公司接待人 员姓名 | 马科文、季超 | | | 投资者关系活动 | 一、粘胶短纤 ...

证券代码：002172 证券简称：澳洋科技 江苏澳洋科技股份有限公司投资者关系活动记录表 编号：2016-01 | --- | --- | --- | |----------------|-------------------------|---------------------------------------------------------------------------------------------------------------| | | | | | | | 特定对象调研 □分析师会议 | | 投资者关系活动 | □ | 媒体采访 □业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | | | 新华资产 舒良；太平洋证券 程志峰；博道投资 张斌；中海 | | | | 基金 郑辰；天治基金 王漪昆；景泰利丰 马犇；弘尚资产 何 | | 参与单位名称及 | | 志俊；中信证券 陈竹、孙晓晖；平安养老保险 谢昌旭；浙商 | | 人员姓名 | | 证券 戴颖；方正富邦基金 高松；九泰基金 林 ...